论文部分内容阅读
目的 评价血清可溶性肿瘤坏死因子受体Ⅰ (STNFR -Ⅰ )检测的临床应用价值。方法 采用酶联免疫吸附法 (ELISA)对 6 2例肺癌患者及 6 1例健康人进行了STNFR -Ⅰ的测定。结果 肺癌组STNFR -Ⅰ值为 2 .84± 1.8ng/ml,高于健康对照组 0 .93± 0 .2 9ng/ml,两组比较P <0 .0 1,且STNFR -Ⅰ水平随肺癌病期进展而升高 ,Ⅰ、Ⅱ、Ⅲ、Ⅳ期分别为 2 .2 3± 0 .47μg/L、2 .34± 0 .6 8μg/L、2 .6 3±0 .6 7ng/ml、3.5 1± 1.6 2 μg/L。肺癌患者STNFR -Ⅰ阳性率 (80 .7% )超过了血清癌胚抗原 (CEA)的阳性率 (38.7% )。结论 测定血清中STNFR -Ⅰ对肺癌的诊断、分期和预后均有较为实用的临床应用价值。
Objective To evaluate the clinical application of serum soluble tumor necrosis factor receptor I (STNFR-I) detection. Methods Enzyme-linked immunosorbent assay (ELISA) was used to detect STNFR-I in 62 lung cancer patients and 61 healthy people. Results The STNFR-I value of the lung cancer group was 2.84±1.8ng/ml, which was higher than that of the healthy control group (0.993±0.29ng/ml). P<0.01 and STNFR-I levels were associated with lung cancer in the two groups. The stage of disease progressed, with stages I, II, III, and IV being 2.23±0.47μg/L, 2.34±0.68μg/L, and 2.63±0.67ng/ml, respectively. 3.5 1 ± 1.6 2 μg/L. The positive rate of STNFR-I in lung cancer patients (80.7%) exceeded the positive rate of serum carcinoembryonic antigen (CEA) (38.7%). Conclusion The determination of serum STNFR-I has a practical value in the diagnosis, staging and prognosis of lung cancer.